In other words, if the treatment strategy is not changed after primary lesion resistance to TKI, continuous TKI treatment will result in the activation of the TFEB/TFE3-lysosome pathway to trigger RCC metastasis. This evidence concerns the gene TFEB and renal cell adenocarcinoma.